Financials in USD. Standardized financial statements.
A compact view of how Viridian Therapeutics, Inc. turns revenue into operating income and net income.
| Metric | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue? | $70.85M | $302,000 | $314,000 | $1.77M | $2.96M | $1.05M | $4.46M | $8.39M | $4.00M | $3.34M |
| Revenue Growth? | +23359.9% | -3.8% | -82.3% | -40.2% | +182.2% | -76.5% | -46.8% | +109.5% | +20.0% | 0.0% |
| Cost of Revenue? | $0 | $0 | $0 | $0 | $0 | $28.30M | $0 | $30.42M | $19.62M | $2.55M |
| Gross Profit? | $70.85M | $302,000 | $314,000 | $1.77M | $2.96M | -$27.25M | $4.46M | -$22.04M | -$15.62M | $789,000 |
| Gross Margin? | +100.0% | +100.0% | +100.0% | +100.0% | +100.0% | -2595.6% | +100.0% | -262.8% | -390.2% | +23.6% |
| Operating Expenses? | $434.24M | $299.34M | $254.76M | $136.08M | $82.69M | $83.13M | $46.44M | $41.47M | $30.54M | $10.46M |
| Operating Income? | -$363.39M | -$299.04M | -$254.45M | -$134.30M | -$79.73M | -$110.38M | -$41.98M | -$33.08M | -$26.53M | -$12.51M |
| EBITDA? | -$337.19M | -$265.66M | -$235.37M | -$129.13M | -$79.29M | -$40.28M | -$40.75M | -$31.55M | -$25.82M | -$12.51M |
| Income Before Tax | -$342.60M | -$269.95M | -$237.73M | -$129.87M | -$79.41M | -$110.72M | -$41.87M | -$32.70M | -$26.51M | -$12.67M |
| Income Tax Expense | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $95,000 | $95,000 |
| Net Income? | -$342.60M | -$269.95M | -$237.73M | -$129.87M | -$79.41M | -$110.72M | -$41.87M | -$32.70M | -$26.51M | -$12.67M |
| EPS? | $-3.32 | $-3.98 | $-5.31 | $-3.91 | $-6.66 | $-31.20 | $-20.31 | $-16.57 | $-20.66 | $-17.57 |
| Diluted EPS? | $-3.32 | $-3.98 | $-5.31 | $-3.91 | $-6.66 | $-31.20 | $-20.31 | $-16.57 | $-20.66 | $-17.57 |
Revenue, profitability, margins, EPS, and share-count trends over time.
Top-line demand and scale over time
Profit left after direct production costs
Core business profitability before financing and tax
Bottom-line profit after all expenses
Profit allocated to each diluted share
Share count trend that affects EPS quality
Gross, operating, and net margin quality